Heart stents are highly effective at saving lives during a heart attack, but their benefits for people with stable heart disease are more modest and sometimes surprising. The answer to “how effective are stents?” depends almost entirely on why one is being placed. Understanding that distinction is the single most important thing to know about stent effectiveness.
During a Heart Attack, Stents Save Lives
When a coronary artery is suddenly and completely blocked, every minute without blood flow damages heart muscle. Emergency stent placement reopens the artery within minutes, restoring blood supply and dramatically reducing the risk of death. This is the scenario where stents perform at their best, and decades of evidence support their use as the standard of care for acute heart attacks.
The survival benefit is so well established that emergency stent procedures are now tracked as a hospital quality metric. The faster the artery is reopened, the more heart muscle is preserved and the better the long-term outcome. In this context, no one seriously debates whether stents work.
For Stable Heart Disease, the Picture Is Different
Many stents are placed not during emergencies but in people with stable narrowed arteries, often discovered during routine testing. Here, the evidence is far less straightforward. In a landmark trial called ORBITA, researchers did something unusual: they compared stent placement to a sham procedure where patients went through the same preparation but didn’t actually receive a stent. Neither the patients nor their treating physicians knew who got the real procedure. The result was that patients who received stents did not perform significantly better on exercise treadmill tests than those who got the placebo procedure.
That finding challenged a widespread assumption. Stented patients did show reduced signs of restricted blood flow on imaging, but this didn’t translate into a meaningful difference in symptoms or physical performance compared to the sham group. The implication is that for many people with stable chest pain, medications alone may control symptoms just as well as adding a stent.
A large trial called ISCHEMIA, published in the New England Journal of Medicine, reinforced this message by comparing an upfront invasive approach (stents or bypass surgery) to conservative treatment with medications in patients with stable coronary disease. Over several years of follow-up, there was no significant difference in major outcomes like heart attack or death between the two groups.
What Stents Do to Blood Flow and Exercise
Stents do physically improve blood flow. Detailed measurements taken during exercise show that stenting improves peak blood flow velocity, coronary perfusion pressure, and other markers of how well the heart performs under stress. One study found that stenting improved exercise time by 67 seconds compared to a patient’s own pre-stent performance. Peak blood pressure during exercise also increased after stenting, consistent with the heart being able to work harder.
The catch is that when you compare this improvement to what patients experience from optimized medications plus a placebo procedure, the gap narrows considerably. The body’s response to the ritual of a procedure, combined with the real effects of blood-thinning and cholesterol-lowering medications, accounts for a large share of the improvement patients feel. This doesn’t mean stents do nothing for blood flow. They clearly do. It means that for stable disease, the added benefit over good medical therapy is smaller than most people expect.
How Long Modern Stents Last
Today’s drug-eluting stents are coated with medication that slowly releases into the artery wall, discouraging scar tissue from regrowing inside the stent. This was a major improvement over older bare-metal stents. A meta-analysis of over 25,000 patients found that the rate of repeat procedures dropped from 14.7% with bare-metal stents to just 2.5% with newer drug-eluting models within the first year.
After that initial period, drug-eluting stents carry a persistent re-narrowing risk of roughly 1 to 2% per year. That means over five years, somewhere between 5 and 10% of stented patients may need another procedure on the same spot. This is a known tradeoff: while bare-metal stents tend to re-narrow early and then stabilize, drug-eluting stents have a lower but ongoing rate of re-narrowing that continues year after year.
Stent Clotting Risks
The most feared complication of a stent is thrombosis, where a blood clot forms inside the stent and suddenly blocks the artery. In modern practice, this is uncommon. Data from a large clinical trial found that the rate of stent clotting was about 0.8% in the first month, 0.8% between one month and one year, and 0.77% beyond one year. Each of these windows carries less than a 1% risk, and prior studies have reported even lower rates for very late clotting (0.2 to 0.4%).
To keep this risk low, patients take blood-thinning medications after stent placement. Current guidelines recommend two antiplatelet medications together for about one year after a stent is placed following a heart attack. For patients with higher bleeding risk, the second medication can sometimes be dropped after just one month. If you’re also taking a blood thinner for another reason, like atrial fibrillation, the combination period is shortened to one to four weeks before simplifying to fewer medications. These timelines represent a careful balance between preventing clots and avoiding excessive bleeding.
Stents Versus Bypass Surgery
When multiple coronary arteries are severely narrowed, the choice between stents and bypass surgery becomes important. A study tracking over 7,000 patients with three-vessel disease for 10 years found that bypass surgery was associated with lower rates of both overall death and heart-related death compared to stents. The advantage was most pronounced when surgeons used arterial grafts rather than vein grafts.
On the stent side, outcomes were better when only a single artery needed stenting. Patients who required stents in multiple arteries had worse long-term survival. This pattern makes intuitive sense: the more complex the disease, the more bypass surgery’s ability to reroute blood flow around multiple blockages provides a durable advantage over treating each narrowing individually with a stent. For simpler disease affecting one or two arteries, stents typically perform comparably to surgery with a much shorter recovery.
Dissolving Stents Haven’t Delivered
Bioresorbable stents, designed to dissolve after the artery heals, were once expected to be the next leap forward. The idea was appealing: provide temporary scaffolding, then disappear, leaving a normal artery behind. Seven-year results from the COMPARE-ABSORB trial told a different story. The dissolving stents had a failure rate of 6.7% compared to 5.9% for standard drug-eluting stents, and the rate of repeat procedures was twice as high in the dissolving stent group (4.4% versus 2.2%). Rates of heart-related death and heart attack were similar between the two, but the dissolving stents did not demonstrate any superiority. For now, permanent drug-eluting stents remain the standard.
What This Means for You
If you’re having a heart attack, a stent is one of the most effective interventions in modern medicine. If you have stable chest pain or a blockage found on a stress test, the decision is more nuanced. Modern medications for cholesterol, blood pressure, and blood thinning have become so effective that adding a stent on top of them often produces only a small additional benefit for stable patients. That doesn’t mean stents are never appropriate for stable disease, but the expected benefit should be weighed honestly against the risks of a procedure and the commitment to long-term blood-thinning medications afterward.
The number of arteries involved also matters. For single-vessel disease, stents perform well over the long term. For complex three-vessel disease, bypass surgery generally offers better durability. Your specific anatomy, symptoms, and other health conditions all factor into which approach makes the most sense.